O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+4.92%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$11.8B
AUM Growth
+$11.8B
(+3.8%)
Cap. Flow
+$299M
Cap. Flow
% of AUM
2.53%
Top 10 Holdings %
Top 10 Hldgs %
36.93%
Holding
154
New
22
Increased
42
Reduced
28
Closed
21
Top Buys
| 1 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$267M |
| 2 |
Boston Scientific
BSX
|
$145M |
| 3 |
AbbVie
ABBV
|
$124M |
| 4 |
AGN.PRA
Allergan plc.
AGN.PRA
|
$109M |
| 5 |
Community Health Systems
CYH
|
$96.3M |
Top Sells
| 1 |
Perrigo
PRGO
|
$207M |
| 2 |
Zimmer Biomet
ZBH
|
$111M |
| 3 |
MDVN
MEDIVATION, INC.
MDVN
|
$107M |
| 4 |
ACT.PRA
ACTAVIS PLC PFD CONV SER A (IRL)
ACT.PRA
|
$105M |
| 5 |
Stryker
SYK
|
$88.6M |
Sector Composition
| 1 | Healthcare | 87.46% |
| 2 | Financials | 0.24% |
| 3 | Technology | 0.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Biogen
BIIB
$19.4B
| $517M | 4.32% | 1,278,900 +72,100 | +6% | +$29.1M |
|
2
Bristol-Myers Squibb
BMY
$96B
| $516M | 4.31% | 7,751,100 -1,131,700 | -13% | -$75.3M |
|
|
AGN
3
DELISTED
Allergan plc
AGN
| $459M | 3.83% | 1,511,315 -66,872 | -4% | -$20.3M |
|
4
HCA Healthcare
HCA
$94.5B
| $455M | 3.8% | 5,017,400 +609,400 | +14% | +$55.3M |
|
|
5
AbbVie
ABBV
$372B
| $448M | 3.74% | 6,665,000 +1,850,100 | +38% | +$124M |
|
|
CELG
6
DELISTED
Celgene Corp
CELG
| $443M | 3.7% | 3,826,000 +654,000 | +21% | +$75.7M |
|
7
Amgen
AMGN
$155B
| $442M | 3.7% | 2,881,000 -168,000 | -6% | -$25.8M |
|
|
8
Boston Scientific
BSX
$156B
| $384M | 3.21% | 21,680,000 +8,169,000 | +60% | +$145M |
|
|
ALXN
9
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $370M | 3.09% | 2,044,400 +1,478,700 | +261% | +$267M |
|
10
Gilead Sciences
GILD
$140B
| $339M | 2.83% | 2,895,400 -516,000 | -15% | -$60.4M |
|
|
SHPG
11
DELISTED
Shire pic
SHPG
| $315M | 2.64% | 1,306,000 -79,000 | -6% | -$19.1M |
|
|
IPXL
12
DELISTED
Impax Laboratories, Inc.
IPXL
| $309M | 2.59% | 6,739,200 +61,200 | +0.9% | +$2.81M |
|
|
ICPT
13
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $270M | 2.26% | 1,120,000 | – | – |
|
14
Illumina
ILMN
$15.8B
| $251M | 2.1% | 1,151,000 -52,000 | -4% | -$11.4M |
|
15
Molina Healthcare
MOH
$9.8B
| $245M | 2.05% | 3,487,900 +28,800 | +0.8% | +$2.02M |
|
|
RLYP
16
DELISTED
RELYPSA INC COM
RLYP
| $245M | 2.05% | 7,400,000 -1,457,551 | -16% | -$48.2M |
|
17
Neurocrine Biosciences
NBIX
$13.8B
| $243M | 2.03% | 5,094,500 -739,100 | -13% | -$35.3M |
|
18
Incyte
INCY
$16.5B
| $241M | 2.02% | 2,314,500 -308,000 | -12% | -$32.1M |
|
|
HNT
19
DELISTED
HEALTH NET INC
HNT
| $237M | 1.98% | 3,702,200 -159,200 | -4% | -$10.2M |
|
20
Regeneron Pharmaceuticals
REGN
$61.5B
| $236M | 1.97% | 461,800 +40,000 | +9% | +$20.4M |
|
21
Cooper Companies
COO
$13.4B
| $232M | 1.94% | 1,301,400 +10,900 | +0.8% | +$1.94M |
|
22
Thermo Fisher Scientific
TMO
$186B
| $182M | 1.52% | 1,402,000 -409,700 | -23% | -$53.2M |
|
23
McKesson
MCK
$85.4B
| $161M | 1.35% | 718,000 +5,000 | +0.7% | +$1.12M |
|
|
MDVN
24
DELISTED
MEDIVATION, INC.
MDVN
| $161M | 1.35% | 1,413,400 -935,500 | -40% | -$107M |
|
|
BLUE
25
DELISTED
bluebird bio
BLUE
| $161M | 1.35% | 958,300 +407,600 | +74% | +$68.6M |
|